A number of large varieties, with volume procurement results announced (with list)

Pharmaceutical Network January 13 Zhejiang collection, the official results came out on January 11, Zhejiang Pharmaceutical Procurement Center issued "on the announcement of some of Zhejiang Province's drug centralized band procurement results" notice, said that by the provincial health insurance bureau review, officially announced some of Zhejiang Province's drug centralized band procurement results.
According to Saibai Blue combing, according to zhejiang Province, part of the drug concentrated belt procurement selected varieties table, in addition to bright propylene relin injection, reberazole sodium intestinal solution tablets, bear deoxycholic acid capsules, bear deoxycholic acid tablets, injection with a Moxirin sodium clavirate potassium (5:1), injection of cephalosporine sodium, injection of cephalosporine sodium, injection of cephalosporine sodium, compound α-ketonic acid tablets have been selected by enterprises.
Specifically, a total of 10 pharmaceutical companies in Zhejiang Province in the current round of volume procurement, namely, Eiswei (China) Pharmaceuticals, Beijing Faisen Yuscabi Pharmaceutical Co., Ltd., Germany Losan Pharma GmbH, Shuanghe Pharmaceuticals (Hainan), Hebei Tiancheng Pharmaceuticals, Wuhan Puyuan Pharmaceuticals, Shandong Lu Anti-Pharmaceuticals, Suzhou Dongrui Pharmaceuticals, Qilu Pharmaceuticals, Shandong Luoxin Pharmaceuticals Group.
According to Cypress Blue statistics, 10 drug-selecting enterprises, 3 from Group A, 7 from Group B - according to the provisions of the Zhejiang Province collection program, Group A for the original research drugs or competition preparations, Group B for other generic drugs.
note that one pharmaceutical company did not appear on the final shortlist compared to the previously announced results of the proposed election, and the exact reasons were not explained accordingly.
According to Saibai Blue combing, Zhejiang Province's current round of belt procurement progress is as follows: December 9, 2020, Zhejiang Pharmaceutical Procurement Center issued the "Zhejiang Province, part of the drug concentration with volume procurement work programme", announced the reberazole oral normal release dosage form, Bear deoxycholic acid oral normal release agent type, amoxicillin kravi acid injection, light propranilin injection, cephalosporininjection and other 8 drugs to carry out volume procurement.
December 24, 2020, the Zhejiang Pharmaceutical Procurement Center issued the "Public Notice of the Selected Varieties for the Central Band Purchase of Some Drugs in Zhejiang Province", which made public the catalogue of the varieties to be selected.
on January 11th, the final results of the election will be officially announced.
According to Zhejiang regulations, each variety shall be determined according to the total agreed procurement volume of 50% of the total annual drug consumption of all public medical institutions in the province in 2019 (including military medical institutions, the same as between 2019), of which Groups A and B shall determine the procurement share of all public medical institutions in the province in 2019 (the highest and lowest agreed procurement volume shall be 45% and 5% of the total annual drug use of the variety, respectively).
the remaining dosing quantity other than the agreed purchase amount, medical institutions may still purchase the selected drugs or the unseeded drugs traded online on the provincial drug purchasing platform.
if either group of A and B does not have a selected drug, 50% of the agreed purchase amount of the group is grouped into another group, and the remaining 50% is used as the remaining amount other than the agreed purchase amount.
the procurement cycle for the current round of collection in Zhejiang Province is still 12 months.
It is worth noting that Zhejiang Province, the Ministry of Health and Health Commission, as the same variety A, B two groups at the same time, public medical institutions in the use of this variety, can break through the "one product, two rules" limit;
addition, during the procurement cycle, if other centralized purchase prices and volume purchase prices in the province are lower than the selected price in Zhejiang Province, the enterprise shall take the initiative to declare and adjust the selected price.
The first round of collection in Hubei Province, the results of the proposed selection of publicity recently, Wuhan City Pharmaceuticals Joint Procurement Office issued "on the publicity of the first batch of drugs in Hubei Province centralized volume procurement declared varieties of quality level, quality evaluation score and quotation ranking and the proposed selection of varieties notice."
According to the notice, Hubei Province's first batch of centralized drug volume procurement quotation and decryption work has been completed, now will be quotation sorting, reporting enterprises and their varieties quality layering, quality evaluation score, quotation from low to high sorting situation.
publicity period: 11 January to 19 January.
According to the Changjiang Daily, of the 29 injectable varieties successfully purchased in Hubei Province's first centralized drug belt, a total of 110 products were to be selected for the first quality level varieties to achieve a decline to obtain the proposed selection.
the proposed price reduction of drugs compared with the lowest online prices in the country, the highest decline in the proposed price is 85.38 percent, an average decrease of 31.51 percent.
, compared with hubei Province, the highest decline in the proposed selection price reached 96.24 percent, an average decline of 37.94 percent.
According to Saibai Blue combing, the progress of the first round of collection in Hubei is as follows: November 13, 2020, Hubei Health Insurance Bureau issued "on the implementation of the first batch of drugs in Hubei Province centralized belt procurement notice", officially disclosed the first collection of varieties in Hubei Province, a total of 33 - involving doso-tea base, fluoxyxaccharides, epoxysacins, oxyfluorosasacins, amoelin, ticalin and so on.
On December 2, 2020, Wuhan Pharmaceuticals Joint Procurement Office issued a Notice on the Implementation of the Declaration of the First Batch of Drug Concentration in Hubei Province, informed that, according to the previous notice, enterprises to participate in the bargaining will be organized to fill in enterprise information, product information, information maintenance work.
subsequently, the central procurement department of pharmaceutical equipment in Hubei Province issued the Notice of the Implementation Rules for the Purchase of the First Batch of Pharmaceuticals in Hubei Province, and officially announced the varieties, standards and bidding rules for the first batch of drug collection in Hubei Province. the updated list of quantities and varieties of
shows that four varieties, such as lubusilin, fluororossacin (fluororossacin glycol), chloroxilin, perfluorosa, pyridine, pyridine, etc., were kicked out of the range of varieties purchased with volume due to the undeclared pre-purchase quantity of medical institutions, and the number of varieties with volume was changed to 29.
It is worth noting that antibiotics account for 28 of the 29 varieties and are all injectables, and the amount reported is also considerable - of which the total number of amoxicillin/claviric acid specifications exceeds 10 million, of which 1.2g (5:l) is more than 7 million.
addition, the amounts reported by zoxafluorosa, pyridoxirin Shubatan, and pyridoxirintambatan are also considerable.
it is worth noting that for the collection of these 29 drugs, Hubei Province also adopted the corresponding conditions to divide the pharmaceutical companies into two bidding groups.
The first group consists mainly of: new drugs of the national category; drugs over the patent period; evaluation of generics and evaluation preparations through consistency; generic drugs approved by the new registration classification of chemicals and drugs included in the List of Listed Drugs in China; Chinese medicines in confidential state prescriptions; and first-class protection of chinese medicine varieties.
second group is mainly: other GMP-certified drugs and other imported drugs.
addition, according to Hubei Province's program, it will also be for the enterprise's industry ranking, innovation ability, product output, raw materials protection, clinical efficacy, market share, etc. , to carry out a comprehensive evaluation.
addition, Hubei Province also according to the use and price relative to the standard deviation to split the varieties, so as to use a more accurate gradient to reduce the price to split the agreed purchase volume.
the requirements, agreed to purchase quantity other than the amount, pharmaceutical institutions can purchase other appropriate prices through the provincial procurement platform with the common name of non-selected varieties.
, all non-selected varieties with the common name will be included in the monitoring and management, and the purchase amount shall not exceed the selected varieties with the common name.
addition, this batch of non-selected drugs will cease to be used in Wuhan area, and if the non-selected drugs are used due to clinical needs, they shall be implemented in accordance with the provisions of Wuhan City's record-keeping procurement.